EHMT1 and Miyoshi myopathy: G9a depletion and inhibition resulted in impaired MM cell growth and viability both in vitro and in vivo and G9a sensitive the MM cells to G9a/GLP inhibitor UNC0642 including the bortezomib-resistant RPMI 8226 cells (P100v).